A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- Conditions
- Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)MedDRA version: 21.1Level: PTClassification code: 10064770Term: Sinusitis noninfective Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- CTIS2022-502481-24-00
- Lead Sponsor
- Insmed Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 270
Key Inclusion Criteria: • Male or female =18 years old and =75 years old • At least a 12-week history of CRSsNP • Ongoing symptoms of nasal congestion • Blood eosinophil count of =750 cells/µL at Screening • Previous sinonasal surgery for CRS and/or treatment with SCS or antibiotics for CRS within a year of Screening Visit • Received a stable daily dose regimen of MFNS for at least 4 weeks before randomization
Key Exclusion Criteria: • Diagnosis of unilateral or bilateral chronic rhinosinusitis with nasal polyps • Participants who have certain conditions or are receiving certain treatments that could adversely affect the participant’s participation in the study, put the participant at unreasonable risk by participating in the study, or interfere with assessment of the effect of treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method